The olezarsen data presentation provides incremental but not transformative clinical readout; HFF returning toward baseline may temper enthusiasm for NASH/fatty liver potential. Monitor for more definitive Phase 3 results and regulatory filings. No financial guidance or material agreement was announced, so near-term trading likely driven by broader biotech sentiment rather than this filing.
Price Chart
Executive Summary
Ionis reported positive new data from the open-label extension study (CORE-OLE) of olezarsen for severe hypertriglyceridemia at the National Lipid Association Scientific Sessions. Key findings include mean hepatic fat fraction (HFF) levels returning toward baseline after 24 months, a favorable safety profile, and >90% patient retention. The data update is qualitative and does not include definitive efficacy numbers, making the near-term stock impact limited.
Key Facts
- Data presented at NLA Scientific Sessions from CORE-OLE study of olezarsen in severe hypertriglyceridemia
- MRI-PDFF results from 53 patients (approx. 25% of substudy) completing 12 months of treatment with 80 mg dose
- Mean HFF levels returning toward baseline after 24 months of treatment
- Less pronounced HFF changes in patients transitioning from 50 mg to 80 mg dose
- Favorable safety profile and >90% patient retention in CORE-OLE
Financial Impact
Not specified
Risk Factors
- HFF returning toward baseline could signal waning efficacy over long-term treatment
- No quantitative efficacy endpoints (e.g., p-values, absolute reductions) disclosed to assess magnitude
- No update on regulatory timeline or commercial outlook for olezarsen
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-025050 |
| Document: 0001140361-26-025050-index-headers.html | 0001140361-26-025050 |
| Document: 0001140361-26-025050-index.html | 0001140361-26-025050 |
| Document: 0001140361-26-025050.txt | 0001140361-26-025050 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $43.23 | awaiting T+20 | — | $43.42 (+0.44%) |
Oct 23, 2026 4d ago | 8-K | $42.93 | awaiting T+20 | — | $43.42 (+1.14%) |
Oct 21, 2026 6d ago | 8-K | $43.91 | awaiting T+20 | — | $43.42 (−1.12%) |
Oct 21, 2026 6d ago | Institutional Cluster | $43.91 | awaiting T+20 | — | $43.42 (−1.12%) |
Sep 23, 2026 4w ago | 8-K | $43.93 $44.27 | ▲ +0.77% | ▲ +0.09% | $43.42 (−1.16%) |
Sep 4, 2026 7w ago | 8-K | $56.71 $44.00 | ▲ +22.41% | ▲ +24.13% | $43.42 (+23.44%) |
Sep 4, 2026 7w ago | 8-K | $58.09 $43.50 | ▼ −25.12% | ▼ −25.72% | $43.42 (−25.25%) |
Jul 31, 2026 12w ago | Insider Buy | $54.49 $60.36 | ▲ +10.77% | ▲ +9.53% | $43.42 (−20.32%) |
Jul 29, 2026 12w ago | 8-K | $54.04 $63.36 | ▲ +17.25% | ▲ +12.23% | $43.42 (−19.65%) |
Jul 9, 2026 15w ago | 8-K | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.42 (−25.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers